A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: The canary prostate cancer tissue microarray

Advances in Anatomic Pathology

Volumn 20, Issue 1, 2013, Pages 39-44

  Hawley, Sarah ^a   Fazli, Ladan ^g   McKenney, Jesse K ^h   Simko, Jeff ^b,c,e   Troyer, Dean ^i,j   Nicolas, Marlo ^j   Newcomb, Lisa F ^k   Cowan, Janet E ^b   Crouch, Luis ^l   Ferrari, Michelle ^f   Hernandez, Javier ^j   Hurtado Coll, Antonio ^g   Kuchinsky, Kyle ^b   Liew, Janet ^g   Mendez Meza, Rosario ^j   Smith, Elizabeth ⁱ   Tenggara, Imelda ^b   Zhang, Xiaotun ^k   Carroll, Peter R ^c,e   Chan, June M ^c,d,e   Gleave, Martin ^g   Lance, Raymond ⁱ   Lin, Daniel W ^k   Nelson, Peter S ^m   Thompson, Ian M ^j   Feng, Ziding ⁿ   True, Lawrence D ^o   Brooks, James D ^f   more..

^a Canary Foundation   (United States)

^b Institute of Pathology   (United States)

^c Departments of Urology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k Division of Urology   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m Division of Human Biology   (United States)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

^o UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

prognosis; prostate cancer; quota sampling; tissue microarray

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANADA; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TISSUE DISTRIBUTION; TISSUE MICROARRAY; UNITED STATES;

DATABASES, FACTUAL; HUMANS; MALE; PATHOLOGY, CLINICAL; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871741950     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31827b665b     Document Type: Review

References (28)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-914. (Pubitemid 39096421)
3. Raldow A, Hamstra DA, Kim SN, et al. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev. 2010;37:89-96.
4. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-565. (Pubitemid 32916759)
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
6. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
7. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157:120-134.
8. Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2009;75:407-413.
9. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-7012.
10. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597. (Pubitemid 29211767)
11. Bismar TA, Humphrey P, Vollmer RT. Information content of five nomograms for outcomes in prostate cancer. Am J Clin Pathol. 2007;128:803-807. (Pubitemid 350133992)
12. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95:634-635. (Pubitemid 36603708)
13. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300-4305.
14. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest. 1986;55:244-248. (Pubitemid 16017550)
15. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
16. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275-286.
17. Grubb RL IIIrd, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102:1524-1530.
18. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl JMed. 2012;367:203-213.
19. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14-S19. (Pubitemid 47224952)
20. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134-1141. (Pubitemid 44288788)
21. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439. (Pubitemid 41124175)
22. Dong F, Reuther AM, Magi-Galluzzi C, et al. Pathologic stage migration has slowed in the late PSA era. Urology. 2007;70: 839-842. (Pubitemid 350192620)
23. Prentice RL. A case-cohort design for epidemiological cohort studies and disease prevention trials. Biometrika. 1986;73:1-11.
24. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545. (Pubitemid 46054056)
25. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344. (Pubitemid 30422619)
26. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 2001;81:1331-1338. (Pubitemid 32980155)
27. Samuelsen SO. Stratified case-cohort analysis of general cohort sampling designs. Scand J Stat. 2007;34:103-119.
28. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press; 2003:220-223.